Business Standard

Tuesday, December 24, 2024 | 09:40 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Divis Laboratories

RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead

The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation

RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
Updated On : 15 Mar 2023 | 11:35 AM IST

Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%

Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.

Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%
Updated On : 23 Dec 2022 | 12:19 PM IST

Divi's Lab Q2 net profit dips 18% to Rs 494 cr, revenue down to Rs 1,854 cr

Divi's Laboratories on Monday said its consolidated net profit declined by 18 per cent to Rs 494 crore in the second quarter of the current financial year. The drug firm had reported a net profit of Rs 606 crore in the July-September period of last fiscal. Revenue from operations declined to Rs 1,854 crore in the September quarter as against Rs 1,987 crore in the year-ago period. Shares of the company on Monday ended 8.63 per cent at Rs 3,422 apiece on the BSE.

Divi's Lab Q2 net profit dips 18% to Rs 494 cr, revenue down to Rs 1,854 cr
Updated On : 07 Nov 2022 | 4:39 PM IST

Divis Labs sheds 14% in two days, hits 52-week low post Q4 results

The company has earmarked an aggressive capex of around Rs 2,000 crore over next two years in order to take a chunk of around $20 billion opportunity of APIs going off-patent over FY23-25.

Divis Labs sheds 14% in two days, hits 52-week low post Q4 results
Updated On : 24 May 2022 | 10:02 AM IST

Divis Labs falls 9% on weak operational performance in September quarter

Ebitda margin contracted by 180 basis points year-on-year to 41.5 per cent in Q2FY22 due to higher other expenses/employee costs.

Divis Labs falls 9% on weak operational performance in September quarter
Updated On : 08 Nov 2021 | 10:17 AM IST

Divis Labs surges 10%, hits record high in Monday's session; here's why

Merck & Co's Covid-19 antiviral pill, Molnupiravir, reduced the risk of hospitalisation or death by 50 per cent

Divis Labs surges 10%, hits record high in Monday's session; here's why
Updated On : 04 Oct 2021 | 11:05 AM IST

Divi's Labs gains 3%, hits new high on strong March quarter results

The board has recommended a dividend of Rs 20 (i.e. 1,000 per cent) per equity share of face value Rs 2 each for the financial year 2020-21

Divi's Labs gains 3%, hits new high on strong March quarter results
Updated On : 31 May 2021 | 9:40 AM IST

Divi's Labs m-cap crosses Rs 1 trillion; stock zooms 109% in CY 2020 so far

Currently, Divis Labs stands at the 30th position among companies having market-cap of over Rs 1 trillion.

Divi's Labs m-cap crosses Rs 1 trillion; stock zooms 109% in CY 2020 so far
Updated On : 17 Dec 2020 | 10:58 AM IST

Divi's Laboratories surges 6%, hits a record high on strong Q2 numbers

Q2FY21 EBITDA margins expanded 843 bps YoY to 42.4 per cent due to significantly better gross margin performance and lower other expenditure.

Divi's Laboratories surges 6%, hits a record high on strong Q2 numbers
Updated On : 09 Nov 2020 | 9:57 AM IST
Updated On : 21 Aug 2020 | 4:00 PM IST

Should you buy Divi's Lab, SBI Life before they enter Nifty50 in September?

Changes have been made in several indices, including Nifty 500, Nifty 200, Nifty 100 and Nifty Midcap 150

Should you buy Divi's Lab, SBI Life before they enter Nifty50 in September?
Updated On : 21 Aug 2020 | 10:29 AM IST

Divi's Lab hits new high as Chippada unit gets zero USFDA observations

In the past month, Divi's Lab has outperformed the market by surging 10 per cent, as compared to 1.4 per cent decline in the S&P BSE Sensex

Divi's Lab hits new high as Chippada unit gets zero USFDA observations
Updated On : 01 Feb 2020 | 10:33 AM IST

Top stock recommendations by Anand Rathi: Buy Divis Labs, Godfrey Phillips

Stock calls by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Top stock recommendations by Anand Rathi: Buy Divis Labs, Godfrey Phillips
Updated On : 01 Oct 2019 | 7:39 AM IST

Divi's Laboratories slips 9% on subdued June quarter results

Operational revenue during the quarter grew 17 per cent YoY at Rs 1,163 crore against Rs 995 crore in the corresponding quarter of previous year

Divi's Laboratories slips 9% on subdued June quarter results
Updated On : 13 Aug 2019 | 10:10 AM IST

Divis Laboratories on strong growth trend, experts expect margins to expand

Strong demand for active ingredients is further accentuated by shortages even as prospects in custom synthesis business remain firm

Divis Laboratories on strong growth trend, experts expect margins to expand
Updated On : 24 Apr 2019 | 1:23 AM IST

Divis Laboratories' Q3 net profit rises 69% to Rs 379.49 cr; revenue up 30%

Divis Labs had reported a net profit of Rs 397.65 crore on total revenue of Rs 1,365 crore in the quarter ended September 2018

Divis Laboratories' Q3 net profit rises 69% to Rs 379.49 cr; revenue up 30%
Updated On : 02 Feb 2019 | 6:29 PM IST

Divis Laboratories to spend Rs 15 billion on expansion by next year

The company said it would be investing Rs 6 billion each on its Unit-2 at the Vizag SEZ in Andhra and Unit-1 of its Nalgonda SEZ in Telangana

Divis Laboratories to spend Rs 15 billion on expansion by next year
Updated On : 30 Oct 2018 | 5:30 AM IST

Divi's Labs gains as USFDA closes out warning letter for Vizag unit

Thus far in the current month, Divi's Labs outperformed the market by gaining 23% after the company on November 2, said that the USFDA will lift import alert for its Visakhapatnam unit.

Divi's Labs gains as USFDA closes out warning letter for Vizag unit
Updated On : 10 Nov 2017 | 10:00 AM IST

Resolved all issues leading to USFDA import alert on Vizag unit: Divis Labs

BS ReporterHyderabad, 20 September: Hyderabad-based Divis Laboratories Limited on Wednesday said Unit 2 in Visakhapatnam, which has been under import alert for the past six months, has resolved all the previous observations of the US Food and Drug Administration(USFDA) in a latest full cGMP verification conducted by the inspection teamThe successful implementation of post-audit corrective plan as indicated by the company will pave the way for lifting of import alert issued under clause 66-40 related to manufacturing side issues. Responding to the news, the company scrip rose as much as 8.13 percent or by Rs 70 at Rs 934 in the afternoon trade on Bombay Stock Exchange.While clearing the plant level issues related to the previous set of observations, the USFDA team has issued a Form 483 with a set of 6 fresh observation following during its audit conducted from September 11-19. Without giving any specific details, Divis management stated that the new set of observations were of ...

Resolved all issues leading to USFDA import alert on Vizag unit: Divis Labs
Updated On : 20 Sep 2017 | 5:17 PM IST

USFDA issues warning letter to Divis Labs for Vishakhapatnam unit

Company, however, did not provide details of the warning letter

USFDA issues warning letter to Divis Labs for Vishakhapatnam unit
Updated On : 22 Apr 2017 | 4:51 PM IST